Adarx Pharmaceuticals initiates coverage with overweight rating; target price $32
ADRX•Morgan Stanley initiated coverage of Adarx Pharmaceuticals with an overweight rating and a $32 target price.
Related News
Beyond Oil receives initial order worth about USD 75,600 from Romanian distributor
BOIL•
France's Macron vows no repeat of riots as Yellow Vests mobilise
TLT•
Trinity Capital Inc: Clear Street raises target price to $19 from $18
TRIN•
Analysts positive on Halliburton after 2027 outlook
HAL•
Capital Southwest Corporation: Clear Street raises target price to $25 from $24
CSWC•